Horizon Discovery Group PLC’s (HZD) “Speculative Buy” Rating Reiterated at Beaufort Securities
Other equities research analysts have also issued research reports about the stock. Panmure Gordon restated a buy rating and issued a GBX 270 ($3.60) price target on shares of Horizon Discovery Group PLC in a report on Tuesday, September 13th. Numis Securities Ltd restated a buy rating and issued a GBX 252 ($3.36) price target on shares of Horizon Discovery Group PLC in a report on Wednesday, September 7th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Horizon Discovery Group PLC presently has a consensus rating of Buy and an average target price of GBX 231.50 ($3.08).
Horizon Discovery Group PLC (LON:HZD) opened at 165.92 on Wednesday. The firm has a 50-day moving average of GBX 160.15 and a 200 day moving average of GBX 160.49. Horizon Discovery Group PLC has a 52-week low of GBX 125.00 and a 52-week high of GBX 188.06. The company’s market capitalization is GBX 156.11 million.
Horizon Discovery Group PLC Company Profile
Horizon Discovery (LSE: HZD) is a world-leading gene editing company that designs and engineers genetically-modified cells, applying them in research and clinical applications to advance human health. Horizon’s proprietary gene editing platform, able to alter almost any gene sequence, has generated a catalogue of over 23,000 cell and in vivo models that recapitulate the genetic anomalies found in diseases like cancer.
Receive News & Ratings for Horizon Discovery Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Discovery Group PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.